YaoRongQuan DataMonitoring shows: Recently, British multinational pharmaceutical company GSK is engaged in in-depth merger and acquisition negotiations with clinical-stage biopharmaceutical company Nuvalent. The potential transaction is valued between $9 billion and $10 billion.

Reportedly, both parties are striving to finalize the definitive agreement within this week. Currently, neither Nuvalent nor GSK has responded to the news. Nuvalent’s current market capitalization is close to $7 billion.

Related Reading: In-depth Investigation by PharmCube Circle Two Years Ago

What Does a Biotech Company Valued at $4 Billion Look Like?

Active M&A in the Global Biopharmaceutical Industry: Major Multinational Corporations (MNCs) Are Expanding Their Oncology R&D Pipelines Through Acquisitions to Fill Gaps Caused by the Patent Cliff; Nuvalent is primarily focused on the development of precision targeted therapies for cancer, with its lead pipeline centered on ROS1 and ALK targets in non-small cell lung cancer (NSCLC). Both of its core candidate drugs have entered the U.S. FDA review stage. Among them, the ROS1 inhibitor Zidesamtinib (NVL-520) has received Breakthrough Therapy Designation and Orphan Drug Status due to its superior blood-brain barrier penetration and efficacy against resistance mutations. Its New Drug Application (NDA) is currently under review, with a prescribed PDUFA action date of September 18, 2026.

In the pivotal clinical trial, the drug achieved an objective response rate of 67% and an intracranial response rate of 75% in the pretreated patient population.

Another next-generation ALK inhibitor, neladalkib (NVL-655), also demonstrates excellent efficacy in treating brain metastases. In clinical trials involving previously treated patients, the objective response rate was 51%, and the intracranial response rate was 64%. The New Drug Application for this agent has been granted Priority Review by the FDA, with a prescription drug user fee act (PDUFA) date set for November 27, 2026. Meanwhile, a Phase III comparative trial evaluating its use as first-line therapy was initiated in July 2025.

The simultaneous advancement of two investigational drugs toward market approval may position Nuvalent to become the first company globally this year to secure approvals for both a next-generation ROS1 and an ALK targeted inhibitor. This would enable coverage of various clinical scenarios in ROS1- and ALK-positive non-small cell lung cancer (NSCLC), including first-line and later-line treatment, brain metastases, and drug resistance, thereby effectively addressing existing gaps in clinical therapy.

Nuvalent, Inc. (NASDAQ: NUVL), incorporated in Delaware, United States, on January 25, 2017, is a clinical-stage biopharmaceutical company focused on developing novel, precision-targeted therapies for cancer patients.Acquired After 10 Years: A Hard-Won Achievement! GSK just officially announced the acquisition, with a valuation of $10.6 billion!

Attachment, Note:

Follow the "YaoRongQuan" WeChat Official Account below. For study, exchange, and sharing purposes only; no investment advice or opinions are provided!

References:

Pharmaceutical Circle Data;

https://www.nuvalent.com/；

https://investors.nuvalent.com/；

https://biz.chosun.com；

https://www.sec.gov/Archives/edgar/data；

pharma.bcpmdata.com；

http://www.marketscreener.com；

https://www.businesswire.com；

www1.hkexnews.hk/；

Wait.